186铼-依替膦酸盐。姑息性放射性核素治疗疼痛性骨转移瘤的疗效。
186Re-etidronate. Efficacy of palliative radionuclide therapy for painful bone metastases.
作者信息
Han S H, De Klerk J M, Zonnenberg B A, Tan S, Van Rijk P P
机构信息
Department of Nuclear Medicine, University Medical Center Utrecht, The Netherlands.
出版信息
Q J Nucl Med. 2001 Mar;45(1):84-90.
Pain palliation with bone-seeking radiopharmaceuticals is an effective treatment modality in patients with advanced metastatic bone cancer. Several studies have shown encouraging clinical results of palliative therapy using 186Re-HEDP, with an overall reported response rate of +/-71% for painful osseous metastasized prostate and breast cancer patients. 186Re-HEDP is a very potential isotope with numerous advantageous characteristics for this purpose. Myelosuppressive toxicity is limited and reversible, which makes repetitive treatment safe. However, individual studies are difficult to compare, and are hampered by the numerous and different methods used to assess clinical response. Standardized clinical response assessment using the objective multi-dimensional pain evaluation model should therefore be implemented.
用亲骨性放射性药物缓解疼痛是晚期转移性骨癌患者的一种有效治疗方式。多项研究表明，使用186Re-HEDP进行姑息治疗的临床结果令人鼓舞，据报道，疼痛性骨转移前列腺癌和乳腺癌患者的总体缓解率为±71%。186Re-HEDP是一种非常有潜力的同位素，为此具有许多有利特性。骨髓抑制毒性有限且可逆，这使得重复治疗是安全的。然而，个别研究难以比较，并且受到用于评估临床反应的众多不同方法的阻碍。因此，应采用客观的多维疼痛评估模型进行标准化临床反应评估。
Zotero 插件